Pellegrini, Angelica
Motta, Chiara
Bellan Menegussi, Elisa
Pierangelini, Andrea
Viglio, Simona
Coppolino, Francesco
Beninati, Concetta
De Filippis, Vincenzo
Barbieri, Giulia
Pietrocola, Giampiero
Funding for this research was provided by:
CaRiPaRo Foundation Excellence Research Project (BPiTA n. 52012)
Italian Ministry for Universities and Research (MUR-PRIN-2022 n. 2022ZSA2JP)
EU funding within the Next-generation EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (PE00000007, INF-ACT)
Article History
Received: 29 February 2024
Accepted: 17 June 2024
First Online: 22 June 2024
Declarations
:
: The polyclonal antibodies production protocols were approved by the Ethics Committee of the University of Pavia (OPBA permit n° 1909213) and of the University of Messina (OPBA permit n° 1805210) and by the Ministero della Salute of Italy (permit no. 665/2015).
: Not applicable.
: The authors declare no competing interests.